Intravenous resluzimab (IL-5 antibody)

Are you trying to bankrupt the hospital? This is incorrect. Reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5), is only indicated for severe eosinophilic asthma refractory to standard therapies. Amy has mild to moderate asthma, and her exacerbation is clearly triggered by an infection, not by eosinophilic inflammation. There is no evidence to support using reslizumab in this setting. Go back and try again.

  • E

Map: Amy Cruz_ORU (1101)
Node: 20946
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Ivabradine
  • Inhalational fluticasone (glucocorticoid)
  • Ask the patient to walk or change position
  • Opción 1
  • Amoxicillin
  • 37oC, atmospheric O2 levels, 5% CO2 levels.
  • Opción 2
  • Opción 3
  • 37oC, atmospheric O2 levels, atmospheric CO2 levels.
  • Inhalational cromoglicate
  • Verapamil (calcium channel blocker)
  • Continued focus on the app
  • Ca să nu ne facă observație instructorul de laborator
  • Oral prednisolone (glucocorticoid)
  • Intravenous resluzimab (IL-5 antibody)

Reminder

empty_reminder_msg

FINISH

Time is up